Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.
We have recently defined "immunogenic modulation," a mechanism whereby malignant cells that survive anticancer therapy, due to sublethal delivery or development of treatment resistance, become nonetheless more sensitive to killing by cytotoxic T lymphocytes. This mechanism can be exploited to identify which therapies will best synergize with immunotherapy, potentially maximizing patient clinical benefit.
Laboratory of Tumor Immunology and Biology; Center for Cancer Research, National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
James W
JW
Hodge
Laboratory of Tumor Immunology and Biology; Center for Cancer Research, National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
Anna
A
Kwilas
Laboratory of Tumor Immunology and Biology; Center for Cancer Research, National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
Andressa
A
Ardiani
Laboratory of Tumor Immunology and Biology; Center for Cancer Research, National Cancer Institute; National Institutes of Health; Bethesda, MD USA.
Sofia R
SR
Gameiro
CTL-mediated lysis; antigen-processing machinery; calreticulin; immunogenic modulation; immunotherapy; therapeutic cancer vaccine